HopeStage
Back to overview

Bipolarity studies

Topics

More filters

Study design
Intervention type
Study phase

Bipolarity

Bipolarity involves episodes of depression and periods of elevated or irritable mood, with unusually high energy and activity.

77studies shown
Showing 1-12 of 77
Drug study icon
RecruitingNCT06951711

KarXT for mania in bipolarity: BALSAM-2 study

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

Read the official source — NCT06951711
What is this study about?

Researchers compare KarXT with placebo during a three-week hospital treatment period for people with bipolarity type I experiencing mania, with or without mixed features. They assess changes in manic symptoms and monitor safety.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, China, Croatia, + 8 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT07288320

NBI-1117568 for manic episodes in adults with bipolarity

About this title

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

Read the official source — NCT07288320
What is this study about?

Researchers compare NBI-1117568 with placebo to find out whether it reduces manic symptoms in adults with bipolarity type I who are experiencing mania, with or without mixed features. They also assess safety and how the medicine behaves in the body.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
RecruitingNCT07140913

KarXT with lithium, valproate, or lamotrigine for mania in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Read the official source — NCT07140913
What is this study about?

Researchers compare KarXT with placebo, each added to lithium, valproate or lamotrigine, in people with bipolarity type I experiencing mania, with or without mixed features. They want to know whether adding KarXT improves manic symptoms and assess its safety.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, France, Argentina, + 10 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06951698

KarXT for manic episodes in bipolarity

About this title

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

Read the official source — NCT06951698
What is this study about?

Researchers compare KarXT with placebo to find out whether it reduces manic symptoms in people with bipolarity type I. They also assess side effects and safety during treatment.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States, Australia, New Zealand, + 6 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)
Drug study icon
RecruitingNCT06696755

Icalcaprant for adults living with bipolarity and experiencing depression

About this titleRead the official source — NCT06696755
What is this study about?

Researchers compare two doses of icalcaprant with placebo to find out whether the medicine improves depression symptoms in adults with bipolarity type I or II. Participants take capsules for six weeks while researchers also monitor side effects.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States
Sponsor
AbbVie
Drug study icon
RecruitingNCT07213466

Tailored weight-management care for people with bipolarity

About this title

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

Read the official source — NCT07213466
What is this study about?

Researchers study whether patterns of appetite and metabolism can guide the choice of weight-loss medicines for adults with obesity and bipolarity. Participants receive a medicine selected for their obesity profile, while researchers assess the approach’s feasibility and effects.

Recruiting in the United States
BipolarityMedication studyAges 18–65
Countries
United States
Sponsor
Mayo Clinic
Drug study icon
RecruitingNCT07286175

Brenipatide added to usual care to delay relapse in bipolarity

About this title

A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

Read the official source — NCT07286175
What is this study about?

Researchers compare brenipatide with placebo, both added to usual treatment, to find out whether it delays a new mood episode in adults with bipolarity. They monitor changes in symptoms and the safety of the added medicine.

Recruiting in the United States
BipolarityMedication studyAges 18–75
Countries
United States, Argentina, Brazil, + 4 others
Sponsor
Eli Lilly and Company
Other study type icon
RecruitingNCT06081426

Ketogenic diet and brain, metabolism and emotions during bipolarity

About this title

Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

Read the official source — NCT06081426
Official study title

Elucidating Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD): a Multidisciplinary Mechanistic Study

Recruiting in the United States
BipolarityInterventional studyAges 18–40
Countries
United States
Sponsor
University of Pittsburgh
Device study icon
RecruitingNCT06274567

Active or sham theta-burst stimulation for emotion regulation in bipolarity

About this title

Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder

Read the official source — NCT06274567
Official study title

Targeting Emotion Regulation in Bipolar Disorder With Intermittent Theta Burst Stimulation: A Mechanistic Study

Recruiting in the United States
BipolarityDevice studyAges 24–65
Countries
United States
Sponsor
Massachusetts General Hospital (Hospital / academic medical center)
Drug study icon
RecruitingNCT06929273

Long-term safety of KarXT in bipolarity type I

What is this study about?

This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.

Recruiting in the United States
BipolarityMedicationAges 18–65
Countries
United States, Australia, France, + 17 others
Sponsor
Bristol-Myers Squibb (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.